Annual CFO
-$10.97 M
+$803.10 K+6.82%
30 June 2024
Summary:
Renovaro Biosciences annual cash flow from operations is currently -$10.97 million, with the most recent change of +$803.10 thousand (+6.82%) on 30 June 2024. During the last 3 years, it has risen by +$9.64 million (+46.77%). RENB annual CFO is now -54213.86% below its all-time high of -$20.20 thousand, reached on 01 December 2011.RENB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$2.02 M
+$397.50 K+16.47%
30 September 2024
Summary:
Renovaro Biosciences quarterly cash flow from operations is currently -$2.02 million, with the most recent change of +$397.50 thousand (+16.47%) on 30 September 2024. Over the past year, it has increased by +$1.13 million (+35.92%). RENB quarterly CFO is now -83912.50% below its all-time high of -$2400.00, reached on 01 March 2013.RENB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$10.21 M
+$760.90 K+6.94%
30 September 2024
Summary:
Renovaro Biosciences TTM cash flow from operations is currently -$10.21 million, with the most recent change of +$760.90 thousand (+6.94%) on 30 September 2024. Over the past year, it has increased by +$1.28 million (+11.16%). RENB TTM CFO is now -243007.14% below its all-time high of -$4200.00, reached on 01 June 2011.RENB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RENB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.8% | +35.9% | +11.2% |
| 3 y3 years | +46.8% | +56.4% | +59.6% |
| 5 y5 years | -29.0% | +21.7% | -9.4% |
RENB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +46.8% | at high | +56.4% | at high | +60.3% |
| 5 y | 5 years | -29.0% | +46.8% | at high | +84.5% | -9.4% | +60.3% |
| alltime | all time | <-9999.0% | +46.8% | <-9999.0% | +84.5% | <-9999.0% | +60.3% |
Renovaro Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.02 M(-16.5%) | -$10.21 M(-6.9%) |
| June 2024 | -$10.97 M(-6.8%) | -$2.41 M(-8.4%) | -$10.97 M(+1.4%) |
| Mar 2024 | - | -$2.63 M(-16.3%) | -$10.82 M(-5.9%) |
| Dec 2023 | - | -$3.15 M(+13.3%) | -$11.49 M(-3.4%) |
| Sept 2023 | - | -$2.78 M(+22.8%) | -$11.90 M(+1.0%) |
| June 2023 | -$11.77 M(-25.2%) | - | - |
| June 2023 | - | -$2.26 M(-31.6%) | -$11.77 M(-6.3%) |
| Mar 2023 | - | -$3.31 M(-6.9%) | -$12.56 M(+4.3%) |
| Dec 2022 | - | -$3.55 M(+33.8%) | -$12.04 M(-8.2%) |
| Sept 2022 | - | -$2.65 M(-13.0%) | -$13.11 M(-16.7%) |
| June 2022 | -$15.73 M(-23.7%) | -$3.05 M(+9.5%) | -$15.73 M(-38.8%) |
| Mar 2022 | - | -$2.78 M(-39.7%) | -$25.71 M(+1.8%) |
| Dec 2021 | - | -$4.62 M(-12.4%) | -$25.26 M(+9.2%) |
| Sept 2021 | - | -$5.28 M(-59.5%) | -$23.13 M(+12.2%) |
| June 2021 | -$20.61 M(+97.1%) | -$13.03 M(+458.9%) | -$20.61 M(+109.7%) |
| Mar 2021 | - | -$2.33 M(-6.6%) | -$9.83 M(-13.3%) |
| Dec 2020 | - | -$2.50 M(-9.4%) | -$11.34 M(-0.7%) |
| Sept 2020 | - | -$2.76 M(+22.7%) | -$11.41 M(+9.1%) |
| June 2020 | -$10.46 M(+22.9%) | -$2.25 M(-41.5%) | -$10.46 M(+0.3%) |
| Mar 2020 | - | -$3.84 M(+49.1%) | -$10.43 M(+11.8%) |
| Dec 2019 | - | -$2.58 M(+43.0%) | -$9.33 M(+9.6%) |
| Sept 2019 | - | -$1.80 M(-18.8%) | -$8.51 M(+0.0%) |
| June 2019 | -$8.51 M(+96.1%) | -$2.22 M(-19.0%) | -$8.51 M(+7.7%) |
| Mar 2019 | - | -$2.74 M(+56.1%) | -$7.90 M(+14.6%) |
| Dec 2018 | - | -$1.75 M(-2.4%) | -$6.89 M(+22.5%) |
| Sept 2018 | - | -$1.80 M(+11.5%) | -$5.63 M(+29.7%) |
| June 2018 | -$4.34 M | -$1.61 M(-7.0%) | -$4.34 M(+34.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$1.73 M(+255.2%) | -$3.23 M(+112.0%) |
| Dec 2017 | - | -$487.70 K(-3.8%) | -$1.52 M(+12.0%) |
| Sept 2017 | - | -$506.90 K(+1.6%) | -$1.36 M(+15.3%) |
| June 2017 | -$1.18 M(-20.0%) | -$499.00 K(+1701.4%) | -$1.18 M(+19.1%) |
| Mar 2017 | - | -$27.70 K(-91.5%) | -$988.80 K(-5.0%) |
| Dec 2016 | - | -$324.30 K(-0.7%) | -$1.04 M(-24.8%) |
| Sept 2016 | - | -$326.50 K(+5.2%) | -$1.38 M(-6.1%) |
| June 2016 | -$1.47 M(-61.6%) | -$310.30 K(+291.8%) | -$1.47 M(+26.7%) |
| Mar 2016 | - | -$79.20 K(-88.1%) | -$1.16 M(-62.8%) |
| Dec 2015 | - | -$666.80 K(+60.3%) | -$3.13 M(-7.8%) |
| Sept 2015 | - | -$416.00 K(-79.6%) | -$3.39 M(-6.8%) |
| June 2015 | -$3.83 M(+88.3%) | - | - |
| Mar 2015 | - | -$2.04 M(+119.5%) | -$3.64 M(+79.0%) |
| Dec 2014 | -$2.03 M(+6658.1%) | -$931.20 K(+102.0%) | -$2.03 M(+81.7%) |
| Sept 2014 | - | -$461.00 K(+125.8%) | -$1.12 M(+67.5%) |
| June 2014 | - | -$204.20 K(-53.3%) | -$668.40 K(+41.9%) |
| Mar 2014 | - | -$437.70 K(+2505.4%) | -$471.20 K(+1212.5%) |
| Dec 2013 | - | -$16.80 K(+73.2%) | -$35.90 K(+25.1%) |
| Sept 2013 | - | -$9700.00(+38.6%) | -$28.70 K(+10.4%) |
| June 2013 | - | -$7000.00(+191.7%) | -$26.00 K(-13.3%) |
| Mar 2013 | -$30.10 K(+20.9%) | -$2400.00(-75.0%) | -$30.00 K(-7.4%) |
| Dec 2012 | - | -$9600.00(+37.1%) | -$32.40 K(-4.4%) |
| Sept 2012 | - | -$7000.00(-36.4%) | -$33.90 K(+6.6%) |
| June 2012 | - | -$11.00 K(+129.2%) | -$31.80 K(+27.2%) |
| Mar 2012 | -$24.90 K(+23.3%) | -$4800.00(-56.8%) | -$25.00 K(+23.8%) |
| Dec 2011 | -$20.20 K | -$11.10 K(+126.5%) | -$20.20 K(+122.0%) |
| Sept 2011 | - | -$4900.00(+16.7%) | -$9100.00(+116.7%) |
| June 2011 | - | -$4200.00 | -$4200.00 |
FAQ
- What is Renovaro Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Renovaro Biosciences?
- What is Renovaro Biosciences annual CFO year-on-year change?
- What is Renovaro Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Renovaro Biosciences?
- What is Renovaro Biosciences quarterly CFO year-on-year change?
- What is Renovaro Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Renovaro Biosciences?
- What is Renovaro Biosciences TTM CFO year-on-year change?
What is Renovaro Biosciences annual cash flow from operations?
The current annual CFO of RENB is -$10.97 M
What is the all time high annual CFO for Renovaro Biosciences?
Renovaro Biosciences all-time high annual cash flow from operations is -$20.20 K
What is Renovaro Biosciences annual CFO year-on-year change?
Over the past year, RENB annual cash flow from operations has changed by +$803.10 K (+6.82%)
What is Renovaro Biosciences quarterly cash flow from operations?
The current quarterly CFO of RENB is -$2.02 M
What is the all time high quarterly CFO for Renovaro Biosciences?
Renovaro Biosciences all-time high quarterly cash flow from operations is -$2400.00
What is Renovaro Biosciences quarterly CFO year-on-year change?
Over the past year, RENB quarterly cash flow from operations has changed by +$1.13 M (+35.92%)
What is Renovaro Biosciences TTM cash flow from operations?
The current TTM CFO of RENB is -$10.21 M
What is the all time high TTM CFO for Renovaro Biosciences?
Renovaro Biosciences all-time high TTM cash flow from operations is -$4200.00
What is Renovaro Biosciences TTM CFO year-on-year change?
Over the past year, RENB TTM cash flow from operations has changed by +$1.28 M (+11.16%)